Population pharmacokinetics of intravenous polymyxin B in critically Ill patients: Implications for selection of dosage regimens

Clinical Infectious Diseases

Volumn 57, Issue 4, 2013, Pages 524-531

  Sandri, Ana M ^a   Landersdorfer, Cornelia B ^b,c   Jacob, Jovan ^b   Boniatti, Márcio M ^d   Dalarosa, Micheline G ^e   Falci, Diego R ^e   Behle, Tainá F ^d   Bordinhão, Rosaura C ^e   Wang, Jiping ^b   Forrest, Alan ^c   Nation, Roger L ^b   Li, Jian ^b   Zavascki, Alexandre P ^d  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY AT BUFFALO   (United States)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^e HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

Author keywords

Dose selection; Pharmacokinetics; Plasma protein binding; Polymyxins; Urinary recovery

Indexed keywords

CREATININE; POLYMYXIN B;

ADULT; AGED; APACHE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CONTINUOUS HEMODIALYSIS; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BINDING; DRUG CLEARANCE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MONTE CARLO METHOD; PRIORITY JOURNAL; STEADY STATE; TANDEM MASS SPECTROMETRY; URINALYSIS;

DOSE SELECTION; PHARMACOKINETICS; PLASMA PROTEIN BINDING; POLYMYXINS; URINARY RECOVERY;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BLOOD CHEMICAL ANALYSIS; BODY WEIGHT; CHROMATOGRAPHY, LIQUID; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMYXIN B; TANDEM MASS SPECTROMETRY; URINE; YOUNG ADULT;

EID: 84880939299     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit334     Document Type: Article

References (25)

1. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6:589-601.
2. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007; 60:1206-15.
3. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333-41.
4. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008; 21:449-65.
5. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:1953-8.
6. Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56:4241-9.
7. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-94.
8. Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008; 47:1298-304.
9. Kwa AL, Lim TP, Low JG, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant gram-negative bacterial infections. Diagn Microbiol Infect Dis 2008; 60:163-7.
10. Kwa AL, Abdelraouf K, Low JG, Tam VH. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis 2011; 52:1280-1.
11. Sandri AM, Landersdorfer CB, Jacob J, et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother 2013; 68:674-7.
12. Bauer RJ. S-ADAPT/MCPEM user's guide (version 1.57). Software for pharmacokinetic, pharmacodynamic MCPEM and population data analysis. Berkeley, CA, 2011.
13. Bulitta JB, Bingolbali A, Shin BS, Landersdorfer CB. Development of a new pre-and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J 2011; 13:201-11.
14. Bulitta JB, Landersdorfer CB. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J 2011; 13:212-26.
15. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65.
16. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47:1766-70.
17. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ. NONMEM user's guides (1989-2009). Ellicott City, MD: Icon Development Solutions, 2009.
18. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 2012; 56:4625-9.
19. Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010; 65:2231-7.
20. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-6.
21. Markou N, Fousteri M, Markantonis SL, et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 2012; 67: 2459-62.
22. Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010; 54:1117-24.
23. Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010; 65:1984-90.
24. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012; 65:80-7.
25. Bricker NS. On the meaning of the intact nephron hypothesis. Am J Med 1969; 46:1-11.